Literature DB >> 18552702

Risk factors for albicans and non-albicans candidemia in the intensive care unit.

Jennifer K Chow1, Yoav Golan, Robin Ruthazer, Adolf W Karchmer, Yehuda Carmeli, Deborah A Lichtenberg, Varun Chawla, Janet A Young, Susan Hadley.   

Abstract

OBJECTIVE: To determine risk factors for bloodstream infections (BSI) with Candida non-albicans (C-NA) species and Candida albicans (CA) among critically ill patients.
DESIGN: Case-control study.
SETTING: Adult medical and surgical intensive care units (ICUs) at two university hospitals. PATIENTS: Consecutive patients with C-NA and CA BSIs from 1995-2005 formed the two case groups. Controls were patients without candidemia who were randomly selected in a ratio of 5:1 and matched by study hospital, ICU type (medical vs. surgical) and by ICU admission date within a 3-month period.
INTERVENTIONS: Data collected included demographics, comorbidities, exposure to antibiotics and antifungals, and ICU factors such as total parenteral nutrition (TPN), blood product transfusions, invasive procedures, central venous catheters, hemodialysis, and mechanical ventilation. We built multivariable logistic regression models, which identified risk factors for C-NA or CA BSIs compared with controls. Variables were adjusted for time-at-risk.
MEASUREMENTS AND MAIN RESULTS: There were 67 patients with C-NA BSIs, 79 patients with CA BSIs, and 780 controls. In multivariable models, factors associated with an increased risk of C-NA compared with controls included major pre-ICU operations [odds ratio; (95% confidence interval)] [2.12; (1.14-3.97)], gastrointestinal procedures [2.24; (1.49-3.38)], enteric bacteremia [3.43; (1.39-8.48)], number of hemodialysis days [6.20; (2.67-14.4)], TPN duration [2.87; (1.40-5.90)], and mean number of red blood cell transfusions [2.72; (1.33-5.58)]. Factors associated with an increased risk of CA BSIs compared to controls were very similar and included major ICU operations [1.26; (1.14-3.97)], enteric bacteremia [3.45; (1.38-8.63)], number of hemodialysis days [3.84; (1.75-8.40)], TPN duration [11.0; (5.52-21.7)] and mean number of red blood cell transfusions [1.97; (0.98-3.99)].
CONCLUSIONS: We found multiple common risk factors for both non-C. albicans and C. albicans BSIs, however we could not differentiate between these two groups based on clinical characteristics alone.

Entities:  

Mesh:

Year:  2008        PMID: 18552702     DOI: 10.1097/CCM.0b013e31816fc4cd

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  33 in total

1.  Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.

Authors:  M A Pfaller; M Castanheira; S R Lockhart; A M Ahlquist; S A Messer; R N Jones
Journal:  J Clin Microbiol       Date:  2012-01-25       Impact factor: 5.948

2.  When and how to cover for fungal infections in patients with severe sepsis and septic shock.

Authors:  Nicolas Allou; Jerome Allyn; Philippe Montravers
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

3.  Risk factors and predictors of mortality of candidaemia among critically ill patients: role of antifungal prophylaxis in its development and in selection of non-albicans species.

Authors:  Matthaios Papadimitriou-Olivgeris; Anastasia Spiliopoulou; Fotini Fligou; Iris Spiliopoulou; Lora Tanaseskou; Georgios Karpetas; Markos Marangos; Evangelos D Anastassiou; Myrto Christofidou
Journal:  Infection       Date:  2017-07-29       Impact factor: 3.553

4.  Cross-resistance between voriconazole and fluconazole for non-albicans Candida infection: a case-case-control study.

Authors:  Y Wang; Q Yang; L Chen; L Liu; R Hao; T Zhang; X Wang; J Lei; J Xie; Y Dong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-06-15       Impact factor: 3.267

5.  Management of invasive candidiasis in the intensive care unit.

Authors:  E Geoffrey Playford; Jeff Lipman; Tania C Sorrell
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

6.  Prospective observational multicenter study to define a diagnostic algorithm for biliary candidiasis.

Authors:  Philipp Lenz; Franziska Eckelskemper; Thomas Erichsen; Tim Lankisch; Alexander Dechêne; Gabriele Lubritz; Frank Lenze; Torsten Beyna; Hansjörg Ullerich; Andre Schmedt; Dirk Domagk
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

7.  Epidemiology of candidemia and impact of infectious disease consultation on survival and care.

Authors:  Arno Mohr; Michaela Simon; Tobias Joha; Frank Hanses; Bernd Salzberger; Florian Hitzenbichler
Journal:  Infection       Date:  2020-02-12       Impact factor: 3.553

Review 8.  [Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine].

Authors:  C Lichtenstern; S Swoboda; M Hirschburger; E Domann; T Hoppe-Tichy; M Winkler; C Lass-Flörl; M A Weigand
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041

Review 9.  Chronic meningitis.

Authors:  Raimund Helbok; Gregor Broessner; Bettina Pfausler; Erich Schmutzhard
Journal:  J Neurol       Date:  2009-02-17       Impact factor: 4.849

10.  Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation.

Authors:  Marya D Zilberberg; Smita Kothari; Andrew F Shorr
Journal:  Crit Care       Date:  2009-06-19       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.